Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 1, 2010, Pages 41-49

  Raoul, Jean Luc ^a   Boucher, Eveline ^b   Rolland, Yan ^c   Garin, Etienne ^a  

^a European University in Brittany   (France)

^b Graduate School of Public Health   (Puerto Rico)

^c Department of Medical Imaging   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 HEXADECYL 1,2,9,9 TETRAMETHYL 4,7 DIAZA 1,10 DECANETHIOL LIPIODOL RE 188; ALPHA FETOPROTEIN; CISPLATIN; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 131; LIPIODOL RE 188; MICROSPHERE; RHENIUM 188; UNCLASSIFIED DRUG; YTTRIUM 90;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ARTERY BLOOD FLOW; ARTIFICIAL EMBOLISM; BETA RADIATION; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RETENTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; GAMMA IRRADIATION; HALF LIFE TIME; HEPATIC ARTERY; HUMAN; HYPERBILIRUBINEMIA; INJECTION SITE EXTRAVASATION; INOPERABLE CANCER; ISOTOPE LABELING; LIVER CELL CARCINOMA; LIVER INJURY; LUNG DISEASE; LUNG FIBROSIS; NEUTROPENIA; OVERALL SURVIVAL; PORTAL VEIN BLOOD FLOW; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION ABSORPTION; RADIOEMBOLIZATION; REVIEW; THROMBOCYTOPENIA; TUMOR VASCULARIZATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; HUMANS; INJECTIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; RADIOISOTOPES; TREATMENT OUTCOME;

EID: 74949104582     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.202     Document Type: Review

References (62)

1. Bosch, F. X., Ribes, J., Diaz, M. & Cleries, R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5-S16 (2004).
2. Altekruse, S. F., McGlynn, K. A. & Reichman, M. E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27, 1485-1491 (2009).
3. Benhamiche, A. M. et al. Time trends and ageperiod-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. J. Hepatol. 29, 802-806 (1998).
4. Bosetti, C., Levi, F., Boffetta, P., Lucchini, F., Negri, E. & La vecchia, C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 48, 137-145 (2008). (Pubitemid 351980469)
5. Collette, S. et al. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann. Oncol. 19, 1117-1126 (2008).
6. Llovet, J. M., Burroughs, A. & Bruix, J. Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003).
7. Jirtle, R. L., Anscher, M. S. & Alati, T. Radiation sensitivity of the liver. Adv. Radiat. Biol. 14, 269-311 (1990).
8. Dawson, L. A. et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 18, 2210-2218 (2000).
9. Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698-711 (2008).
10. Llovet, J. M. & Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37, 429-442 (2003).
11. Llovet, J. M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359, 1734-1739 (2002).
12. Malagari, K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC beads. Expert Rev. Anticancer Ther. 8, 1643-1650 (2008).
13. Gonsalves, C. F., Brown, D. B. & Barr, B. I. Regional radioactive treatments for hepatocellular carcinoma. Expert Rev. Gastroenterol. Hepatol. 2, 453-456 (2008).
14. Lambert, B. et al. 188Re-HDD/lipiodol Therapy for hepatocellular carcinoma: a phase I clinical trial. J. Nucl. Med. 46, 160-166 (2005).
15. Garin, E. et al. 188 Re8SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. Nucl. Med. Comm. 25, 1007-1013 (2005).
16. Salem, R. Radioembolization with 90Y microspheres: a state-of-the-art brachyTherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J. Vasc. Interv. Radiol. 18, 1460-1461 (2007).
17. Raoul, J. L. et al. Hepatic artery injection of I131 labelled lipiodol. I. Biodistribution study results in patients with hepatocellular carcinoma. Radiology 168, 541-545 (1988).
18. Lambert, B. & van de wiele, C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging 32, 980-989 (2005).
19. Madsen, M. T., Park, C. H. & Thakur, M. L. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J. Nucl. Med. 29, 1038-1044 (1988).
20. Becker, S. et al. Dosimetric evaluation and Therapeutic response to internal radiation Therapy of hepatocellular carcinomas using iodine-131-labelled lipiodol. Nucl. Med. Commun. 29, 815-825 (2008).
21. Bretagne, J. F. et al. Hepatic artery injection of I131 labelled lipiodol. II. Preliminary results of Therapeutic use in patients with hepatocellular carcinoma and liver metastases. Radiology 168, 547-550 (1988).
22. Raoul, J. L. et al. Internal radiation Therapy of hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of I131 labeled Lipiodol. Cancer 69, 346-352 (1992).
23. Raoul, J. L. et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J. Nucl. Med. 35, 1782-1787 (1994).
24. Raoul, J. L. et al. Usefulness of hepatic artery injection of I131 Lipiodol in the Therapeutic decision in hepatocellular carcinoma. Scand. J. Gastroenterol. 28, 217-223 (1993).
25. De Baere, T. et al. Hepatic intraarterial 131I iodized oil for the treatment of hepatocellular carcinoma in patients with impeded portal venous flow. Radiology 212, 665-668 (1999).
26. Raoul, J. L. et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131-I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26, 1156-1161 (1997).
27. Lau, w. Y. et al. Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353, 797-801 (1999).
28. Lau, w. Y., Lai, E. C., Leung, T. w. & Yu, S. C. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trialupdate on 5-year and 10-year survival. Ann. Surg. 247, 43-48 (2008).
29. Boucher, E. et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 38, 1237-1241 (2003). (Pubitemid 37314832)
30. Boucher, E., Bouguen, G., Garin, E., Guillygomac'h, A., Boudjema, K. & Raoul, J. L. Adjuvant intra-arterial injection of iodine 131-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5 year minimal follow-up. J. Nucl. Med. 49, 362-366 (2008).
31. Tabone, M., vigano, L., Laudi, C., Ferrero, A., Pellerito, R. & Capussotti, L. Adjuvant iodine-131-labeled lipiodol for prevention of intrahepatic recurrence of hepatocellular carcinoma: which is the best treatment schedule? Hepatology 41, 1433-1434 (2005).
32. Ng, K. M. et al. Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma. HPB (Oxford) 10, 388-395 (2008).
33. Dupont-Bierre, E. et al. Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J. Am. Coll. Surg. 201, 663-670 (2005).
34. Raoul, J. L., Messner, M., Boucher, E., Bretagne, J. F., Campion, J. P. & Boudjema, K. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol. BR. J. Surg. 90, 1379-1383 (2003). (Pubitemid 37421673)
35. Boucher, E., Garin, E., Guillygomac'h, A., Olivie, D., Boudjema, K. & Raoul, J. L. Intraarterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. RadioTher. Oncol. 82, 76-82 (2007).
36. Kishi, K. et al. Acute toxicity of lipiodol infusion into the hepatic arteries of dogs. Invest. Radiol. 29, 882-889 (1994).
37. Marelli, L. et al. Transarterial Therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc. Intervent. Radiol. 30, 6-25 (2007).
38. Garin, E. et al. Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering 131I-lipiodol Therapy for hepatocellular carcinoma. Nucl. Med. Comm. 24, 671-678 (2003).
39. Bernal, P. et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int. J. Radiat. Oncol. Biol. Phys. 69, 1448-1455 (2007).
40. Kumar, A. et al. Inoperable hepatocellular carcinoma: transarterial 188Re-HDD-labeled iodized oil for treatment; prospective multicenter clinical trial. Radiology 243, 509-519 (2007).
41. Ogawa, F. et al. Gastroduodenitis associated with Yttrium90-microsphere selective internal radiation. An iatrogenic complication in need of recognition. Arch. Pathol. Lab. Med. 132, 1734-1738 (2008).
42. Shepherd, F. A. et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 70, 2250-2254 (1992).
43. Salem, R. et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSpheres): safety, tumor response, and survival. J. Vasc. Interv. Radiol. 16, 1627-1639 (2005).
44. Kulik, L. M. et al. Safety and efficacy of 90Y radioTherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47, 71-81 (2008).
45. Forner, A. & Bruix, J. Locoregional treatment for hepatocellular carcinoma: from clinical explorations to robust clinical data, changing standards of care. Hepatology 47, 5-7 (2008).
46. Kulik, L. M. et al. Yttrium-90 microspheres (TheraSphere® ) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J. Surg. Oncol. 94, 572-586 (2006).
47. Riaz, A. et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49, 1185-1193 (2009).
48. Lewandowski, R. J. et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am. J. Transplant. 9, 1920-1928 (2009).
49. Kennedy, A. S. et al. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int. J. Radiat. Oncol. Biol. Phys. 60, 1552-1563 (2004).
50. van Hazel, G. et al. Randomized phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemoTherapy versus fluorouracil/leucovorin chemoTherapy alone in advanced colorectal cancer. J. Surg. Oncol. 88, 78-85 (2004).
51. Gray, B. et al. Randomised trial of SIR-Spheres plus chemoTherapy vs. chemoTherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann. Oncol. 12, 1711-1720 (2001).
52. Sharma, R. A. et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemoTherapy. J. Clin. Oncol. 25, 1099-1106 (2007).
53. van de wiele, C. et al. Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors. Q. J. Nucl. Med. Mol. Imaging 53, 317-324 (2009).
54. Lau, w. Y. et al. Selective internal radiation Therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90Yttrium microspheres. Int. J. Radiat. Oncol. Biol. Phys. 40, 583-592 (1998).
55. Lau, w. Y. et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann. Surg. 240, 299-305 (2004).
56. Sangro, B. et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 66, 792-800 (2006).
57. Kennedy, A. S. et al. Treatment parameters and outcome of 680 treatments of internal radiation with resin (90)Y-microspheres for unresectable hepatic tumors. Int. J. Radiat. Oncol. Biol. Phys. 74, 1494-1500 (2009).
58. Chenoufi, N. et al. In vitro demonstration of synergy between radionuclide and chemoTherapy. J. Nucl. Med. 39, 900-903 (1998).
59. Raoul, J. L. et al. Association of cisplatin and intra-arterial injection of 131I-lipiodol in treatment of hepatocellular carcinoma: results of phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 64, 745-750 (2006).
60. van Hazel, G. et al. Treatment of fluorouracilrefractory patients with liver metastases from colorectal cancer by using Yttrium-90 resin microspheres plus concomitant systemic irinotecan chemoTherapy. J. Clin. Oncol. 27, 4089-4095 (2009).
61. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
62. Divgi, C. The promise of locoregional radiopharmaceutical Therapy: will it ever be realized? J. Nucl. Med. 49, 340 (2008).